Chemical structure of stavudine.
Find information on thousands of medical conditions and prescription drugs.

Stavudine

Stavudine (2'-3'-didehydro-2'-3'-dideoxythymidine, d4T, brand name ZeritĀ®) is a nucleoside analog reverse transcriptase inhibitor (NARTI) active against HIV. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
Growth hormone
Salbutamol
Salmeterol
Sandimmune
Sandostatin
Sansert
Saquinavir
Sarafem
Satric
Scopolamine
Seasonale
Secobarbital
Secretin
Selegiline
Semprex-D
Sensipar
Sensorcaine
Serax
Serevent
Serine
Seroquel
Serostim
Serrapeptase
Sertindole
Sertraline
Serzone
Sevelamer
Sevoflurane
Sibutramine
Sildenafil
Silibinin
Simvastatin
Sinemet
Sinequan
Singulair
Sirolimus
Skelaxin
Sodium cyclamate
Solage
Soma
Somatostatin
Sotahexal
Sotalol
Sotret
Spiperone
Spiriva
Spironolactone
Sporahexal
Sporanox
SPS
SSD
Stanozolol
Stavudine
Stelazine
Stilbestrol
Stilbetin
Stimate
Stiripentol
Strattera
Streptokinase
Streptomycin
Suboxone
Subutex
Sucralfate
Sucralfate
Sufentanil
Sulbactam
Sulfamethoxazole
Sulfanilamide
Sulfasalazine
Sulforidazine
Sulla
Sulpiride
Sultamicillin
Sumatriptan
Suprefact
Suramin sodium
Sustaire
Sustiva
Suxamethonium chloride
Symmetrel
Synarel
Synercid
Synthroid
Syntocinon
Zaleplon
T
U
V
W
X
Y
Z

History

Stavudine was approved by the Food and Drug Administration (FDA) in Jun 24, 1994 for adults and in Sep 6, 1996 for pediatric use and again as an extended-release version for once-a-day dosing in 2001. The fourth antiretroviral drug on the market, its patent will expire in the United States on 2008-06-25.

Mechanism of ation

Stavudine is an analog of thymidine. It is phosphorylated by cellular kinases into active triphosphate. Stavudine triphosphate inhibits the reverse transcriptase by competing with natural substrate, thymidine triphosphate. It also causes termination of DNA synthesis by incorporating into it.

The oral absorption rate of stavudine is over 80 %. Approximately half of stavudine is actively secreted unchanged into the urine and the other half is eliminated through endogenic pathways. Simultaneous use of AZT is not recommended, for AZT can inhibit the intracellular phosphorylation of stavudine. Other anti-HIV drugs do not possess this property. The main severe side effect is peripheral neuropathy, which can be corrected by reducing dosage. Stavudine has been shown in laboratory test to be genotoxic, but with clinical doses its carcinogenic effects are non-existent.

Read more at Wikipedia.org


[List your site here Free!]


d4T and lactic acidosis with neuromuscular weakness: FDA warning - Brief Article
From AIDS Treatment News, 3/8/02

The U.S. Food and Drug Administration emailed the following warning on March 1, 2002. The FDA also reported this information at the 9th Conference on Retroviruses and Opportunistic Infections on February 28 [abstract LB 14].

[Comment: Patients should remember that this warning describes a rare condition associated with drugs that have been used by thousands of people for many years. It may have little impact on treatment decisions. But patients and doctors need to be aware of the possibility, so that patients can get medical attention early if the problem is suspected, and suspend or change their treatment if necessary. JSJ]

"Changes have been made in the WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, and PATIENT INFORMATION sections of the ZERIT (stavudine, d4T) label to describe the occurrence of lactic acidosis and neuromuscular toxicity in patients using stavudine.

A total of 25 patients with neuromuscular weakness resembling Guillain-Barre syndrome in association with lactic acidosis were reported to the FDA's Adverse Event Reporting System. In most cases, antirctroviral therapy was continued in the presence of symptoms that might have been due to lactic acidosis, such as abdominal pain, nausea, and fatigue, leading to death in six of the patients. Most of these patients (22 out of 25) were receiving antiretroviral combinations containing stavudine. Although causality has not been established, these findings were consistent with recent reports in peer-reviewed journals that the use of stavudine in antiretroviral combination therapy may increase the risk of lactic acidosis. Therefore, the stavudine label now includes a warning that its use may increase the risk of lactic acidosis, which represents a rare, but serious adverse event. The label now includes the symptoms of the newly described symptomatic hyperlactemia syndrome, and the recommendation for prompt suspension of all antiretroviral therapy in suspected cases of lactic acidosis with or without neuromuscular weakness. Permanent discontinuation of stavudine should be considered in confirmed cases of lactic acidosis.

Please refer to the Zerit label for full prescribing information. A copy of the revised labeling is available at:

http://www.fda.gov/cder/foi/label/2002/20412S0I7.pdf

Bristol-Myers Squibb Company, which makes and markets Zerit, is distributing a letter to health care providers giving more detailed information. The letter reads:

February 2002

Dear Healthcare Provider,

Bristol-Myers Squibb Company would like to remind healthcare providers caring for persons with HIV of the potential for lactic acidosis as a complication of therapy with nucleoside analogues, including ZERIT (stavudine), d4T. The early signs and symptoms of clinical events associated with hyperlactatemia should receive careful attention because of the life-threatening potential of the most extreme manifestation, lactic acidosis syndrome (LAS).

Bristol-Myers Squibb has received reports of rare occurrences of rapidly ascending neuromuscular weakness, mimicking the clinical presentation of Guillain-Barre syndrome (including respiratory failure), in HIV-infected patients receiving stavudine in combination with other antiretrovirals. Some cases were fatal. Most of the cases were reported in the setting of lactic acidosis or symptomatic hyperlactatemia and, in most, antiretroviral therapy had been continued in the presence of non-specific signs compatible with early symptomatic hyperlactatemia that preceded the development of neuromuscular signs and symptoms. If motor weakness develops in a patient receiving stavudine, the drug should be discontinued.

Confirmed elevations of serum lactate may be associated with a broad spectrum of clinical manifestations, ranging from asymptomatic hyperlactatemia, through symptomatic non-acidotic hyperlactatemia (SHL), to acute severe LAS. Early signs and symptoms associated with a high lactate may be subtle and include generalized fatigue, digestive symptoms (nausea, vomiting, abdominal pain, and sudden unexplained weight loss), respiratory symptoms (tachypnca and dyspnea), or neurologic symptoms (including motor weakness). Patients with these symptoms should promptly interrupt antiretroviral therapy, and a full medical work-up should be performed rapidly. (i) Permanent discontinuation of stavudine should be considered for patients with confirmed LAS. It is important to note that symptoms associated with hyperlactatemia may continue or worsen following discontinuation of antiretroviral therapy.

At this time, prospective monitoring of lactate levels does not appear to be helpful in predicting the subsequent occurrence of SHL or LAS. (i)

Although relative rates of lactic acidosis have not been assessed in prospective well-controlled trials, longitudinal cohort and retrospective studies suggest that this infrequent event may be more often associated with antiretroviral combinations containing stavudine. (ii, iii, iv)

See the enclosed full prescribing information for ZERIT[R] for additional information regarding the recommended use of stavudine. If you have any further questions, please contact the Medical Information Department at Bristol-Myers Squibb Company at 1-800-426-7644.

Sincerely, Michael R. Stevens, PharmD, Vice President, Medical Affairs, Virology

(i). Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS 2001; 15: 795-797.

(ii.) John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIVinfected patients taking antiretroviral therapy. AIDS 2001; 15: 717-723.

(iii.) Lonergan JT, Havlir D, Barber E, Mathews WC. Incidence and Outcome of Hyperlactatemia Associated with Clinical Manifestations in HIV-Infected Adults Receiving NRTI-Containing Regimens. 8th Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 624].

(iv.) Gerard Y, Maulin L, et al. Symptomatic hyperlactatemia: an emerging complication of antiretroviral therapy. AIDS 2000; 14: 2723-2730.

COPYRIGHT 2002 John S. James
COPYRIGHT 2002 Gale Group

Return to Stavudine
Home Contact Resources Exchange Links ebay